Creative Medical Technology (NASDAQ:CELZ) Rating Increased to Sell at Wall Street Zen

Creative Medical Technology (NASDAQ:CELZ) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a research note issued to investors on Saturday.

Creative Medical Technology Stock Performance

Shares of CELZ stock opened at $3.33 on Friday. The stock’s 50-day moving average is $2.66 and its two-hundred day moving average is $2.85. The firm has a market cap of $8.62 million, a price-to-earnings ratio of -0.87 and a beta of 2.04. Creative Medical Technology has a 1 year low of $1.69 and a 1 year high of $6.90.

Creative Medical Technology (NASDAQ:CELZ) last issued its quarterly earnings data on Friday, August 8th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.15. As a group, research analysts predict that Creative Medical Technology will post -3.19 EPS for the current year.

Hedge Funds Weigh In On Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Geode Capital Management LLC purchased a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 10,308 shares of the company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned about 0.59% of Creative Medical Technology as of its most recent SEC filing. 1.42% of the stock is currently owned by institutional investors and hedge funds.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.